Libo Biotechnology

Libo Biotechnology is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of innovative cancer immunotherapies. The company primarily focuses on chimeric antigen receptor T-cell (CAR-T) and TCR-T cell therapies targeting various hematological malignancies and solid tumors. Its pipeline includes candidates targeting well-validated antigens such as CD19, CD20, and BCMA, as well as novel targets for difficult-to-treat cancers. Libo Biotechnology aims to improve the efficacy and safety of cell therapies through its proprietary technology platforms. The company is actively advancing several programs through clinical trials in collaboration with leading medical institutions in China.